Pharma News
Biosimilar partnerships for Alvotech and Pall Biotech
Partnering to develop biosimilars is still in vogue. The latest companies to join the trend include Alvotech with Changchun High & New Technology Industries Group (CCHN) and Pall Corporation’s Biotech business (Pall Biotech) with Aetos Biologics.
Mundipharma buys Spanish biosimilars maker Cinfa Biotech
UK-based Mundipharma International (Mundipharma) is strengthening its position in biosimilars with the acquisition of Spanish biosimilars maker Cinfa Biotech.
MENA mAb manufacturer AryoGen receives EU GMP approval
Iran-based AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified [1].
Co-development deal for ranibizumab biosimilar Xlucane
German generics giant Stada and Swedish biotech company Xbrane announced on 12 July 2018 that they had entered into a co-development agreement for Xlucane, a proposed biosimilar to Lucentis (ranibizumab).
AbbVie signs another licensing deal for adalimumab biosimilar
US-based pharma giant AbbVie has signed yet another licensing deal for a biosimilar version of its blockbuster arthritis drug Humira (adalimumab).
Mylan and Lupin make deal for etanercept biosimilar
Indian generics manufacturer Lupin Pharmaceuticals (Lupin) and US-based drugmaker Mylan announced on 28 June 2018 that they had made a deal to commercialize an etanercept biosimilar.
Pfenex makes biosimilar deals with Alvogen and NT Pharma
US-based biotech firm Pfenex has made commercialization deals for its candidate teriparatide biosimilar (PF708) in China and in the US.
Amneal and mAbxience make deal for bevacizumab biosimilar
US generics maker Amneal Pharmaceuticals (Amneal) and biosimilars specialist mAbxience, a subsidiary of Spanish healthcare firm Insud Pharma (formerly the Chemo Group), announced on 23 May 2018 that they have signed an exclusive licensing and supply agreement in the US for mAbxience’s candidate bevacizumab biosimilar.
Strides and Apotex to merge Australian generics businesses
India-based generics manufacturer Strides Shasun (Strides) announced on 9 May 2018 that it had made an agreement with Canada-based Apotex to merge their Australian businesses.
Sanofi to sell Zentiva generics arm to Advent
French drugmaker Sanofi announced on 17 April 2018 that it had entered into exclusive negotiations with Advent International (Advent) under which Advent would acquire Zentiva, Sanofi’s European generics business for Euros 1.9 billion.
